for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ligand Pharmaceuticals Inc.

LGND.OQ

Latest Trade

131.40USD

Change

0.78(+0.60%)

Volume

18,872

Today's Range

129.88

 - 

132.21

52 Week Range

78.27

 - 

219.73

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
130.62
Open
130.50
Volume
18,872
3M AVG Volume
4.53
Today's High
132.21
Today's Low
129.88
52 Week High
219.73
52 Week Low
78.27
Shares Out (MIL)
16.68
Market Cap (MIL)
2,144.10
Forward P/E
21.69
Dividend (Yield %)
--

Next Event

Q3 2021 Ligand Pharmaceuticals Inc Earnings Release

Latest Developments

More

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results From The Ongoing Phase 3 Protect Study Of Sparsentan In Iga Nephropathy

Ligand Q2 Earnings Per Share $1.79

Ligand Reports First Quarter 2021 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's technology includes Captisol Technology, OmniAb Technologies (OMT), Icagen Ion Channel Technology Platform, Pelican Expression Technology platform and Liver Targeting Prodrug (LTP) Technology to assist companies in their work toward securing prescription drug and biologic approvals. It has partnerships and license agreements with over 130 pharmaceutical and biotechnology companies and over 300 programs that are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its partners and licensees have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.

Industry

Biotechnology & Drugs

Contact Info

3911 Sorrento Valley Blvd Ste 110

SAN DIEGO, CA

92121-1402

United States

+1.858.5507500

https://www.ligand.com/

Executive Leadership

John W. Kozarich

Non-Executive Independent Chairman of the Board

Matthew William Foehr

President, Chief Operating Officer

John L. Higgins

Chief Executive Officer, Director

Matthew Edward Korenberg

Chief Financial Officer, Executive Vice President - Finance

Charles Stuart Berkman

Senior Vice President, General Counsel, Secretary

Key Stats

1.86 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.3K

2019

0.1K

2020

0.2K

2021(E)

0.3K
EPS (USD)

2018

7.150

2019

3.090

2020

4.550

2021(E)

5.927
Price To Earnings (TTM)
46.24
Price To Sales (TTM)
8.52
Price To Book (MRQ)
2.73
Price To Cash Flow (TTM)
23.59
Total Debt To Equity (MRQ)
40.10
LT Debt To Equity (MRQ)
40.09
Return on Investment (TTM)
3.96
Return on Equity (TTM)
3.83

Latest News

Latest News

BRIEF-HitGen Signs Agreement To Buy Vernalis (R&D) Limited For $25 Mln

* SAYS IT SIGNS AGREEMENT WITH LIGAND PHARMACEUTICALS, VERNALIS LIMITED TO BUY VERNALIS (R&D) LIMITED FOR $25 MILLION Source text in Chinese: https://bit.ly/3dnsfUO Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Ligand Announces An Expansion Of Vernalis Collaboration With Servier

* LIGAND ANNOUNCES AN EXPANSION OF VERNALIS COLLABORATION WITH SERVIER FOR RESEARCH ON NOVEL ONCOLOGY TARGETS

BRIEF-Ligand CEO Issues Letter To Captisol Customers

* LIGAND PHARMACEUTICALS - IN JANUARY, GILEAD INFORMED CO THEY NEEDED CAPTISOL FOR REMDESIVIR AS POTENTIAL TREATMENT FOR COVID-19

BRIEF-Ligand Announces Icagen’S Expansion Of Collaboration With Roche To Develop And Commercialize Therapies For Neurological Diseases

* LIGAND ANNOUNCES ICAGEN’S EXPANSION OF COLLABORATION WITH ROCHE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEUROLOGICAL DISEASES

BRIEF-Ligand Earns $3 Mln Milestone Payment From Palvella Therapeutics

* LIGAND EARNS $3 MILLION MILESTONE PAYMENT FROM PALVELLA THERAPEUTICS Source text for Eikon: Further company coverage:

BRIEF-Ligand Pharmaceuticals Says Entered Into Amendments With "Option Counterparties" To Convertible Note Hedge Transactions

* LIGAND PHARMACEUTICALS INC - ON APRIL 6, ENTERED INTO AMENDMENTS WITH "OPTION COUNTERPARTIES" TO CONVERTIBLE NOTE HEDGE TRANSACTIONS Source: https://bit.ly/3bZF45x Further company coverage:

BRIEF-Ligand Says Partners Are Actively Progressing Two Omniab Antibody Discovery Programs For Potential Treatment Of Covid-19

* LIGAND PHARMACEUTICALS - CO'S PARTNERS ARE ACTIVELY PROGRESSING TWO OMNIAB ANTIBODY DISCOVERY PROGRAMS FOR POTENTIAL TREATMENT OF COVID-19

BRIEF-Ligand Completes Acquisition Of Icagen Core Assets, Partnered Programs And Ion Channel Technologies

* LIGAND COMPLETES ACQUISITION OF ICAGEN CORE ASSETS, PARTNERED PROGRAMS AND ION CHANNEL TECHNOLOGIES Source text for Eikon: Further company coverage:

BRIEF-Ligand Sees FY 2020 Earnings Per Share Of $3.62

* LIGAND RAISES 2020 FINANCIAL GUIDANCE DUE TO HIGHER CAPTISOL MATERIAL SALES

BRIEF-Ligand Agrees To Acquire Core Assets, Partnered Programs And Ion Channel Technologies From Icagen

* LIGAND AGREES TO ACQUIRE CORE ASSETS, PARTNERED PROGRAMS AND ION CHANNEL TECHNOLOGIES FROM ICAGEN

BRIEF-Ligand Reports Q4 Adjusted Earnings Per Share $0.71

* LIGAND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

REFILE-BRIEF-Ligand Pharma - Entered A Worldwide Commercial Platform License Agreement With Genagon Therapeutics AB

* LIGAND PHARMACEUTICALS INC - ON FEB 4 ENTERED INTO A WORLDWIDE COMMERCIAL PLATFORM LICENSE AGREEMENT WITH GENAGON THERAPEUTICS AB

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up